Compare iShares MSCI India ETF (INDA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs BIO-TECHNE Corp — how do they compare? iShares MSCI India ETF trades at $45.98 (market cap $5.73B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 57 Days and BIO-TECHNE Corp for 63 Days on average.
| INDA | TECH | |
|---|---|---|
Market Cap | $5.73B | $11.36B |
Volume | 6,797,522 | 5,390,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $72.61 |
52-Week Low | $45.42 | $43.31 |
Typical Hold Time | 57 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA is trading at $46.12, down 1.31% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and U.S. tariff tensions. Technical indicators show oversold conditions with RSI readings below 30, while moving averages signal strong bearish momentum. Recent news highlights structural issues in India's banking-heavy market composition despite overall economic growth.
The outlook remains cautious given India's energy security challenges and external trade pressures. Investment opportunity exists for long-term investors betting on India's growth story at current discounted levels, but risks include persistent power shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
